Evidence map›Paper›PMID 41182459›Full record

ArticleJournal of neuro-oncology2025

Peripheral neural crest tumor brain metastases management: a single-institution retrospective study.

Ahed H Kattaa, Amit R Persad, Yusuke S Hori, Paul M Harary, Muhammad Izhar, Louisa Ustrzynski, Sara C Emrich, Armine Tayag, Susan M Hiniker, David J Park and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ahed H KattaaDepartment of Neurosurgery, Stanford University School of Medicine, 213 Quarry Road, Stanford, CA, 94304, USA.
Amit R PersadDepartment of Neurosurgery, Stanford University School of Medicine, 213 Quarry Road, Stanford, CA, 94304, USA.
Yusuke S HoriDepartment of Neurosurgery, Stanford University School of Medicine, 213 Quarry Road, Stanford, CA, 94304, USA.
Paul M HararyDepartment of Neurosurgery, Stanford University School of Medicine, 213 Quarry Road, Stanford, CA, 94304, USA.
Muhammad IzharDepartment of Neurosurgery, Stanford University School of Medicine, 213 Quarry Road, Stanford, CA, 94304, USA.
Louisa UstrzynskiDepartment of Neurosurgery, Stanford University School of Medicine, 213 Quarry Road, Stanford, CA, 94304, USA.
Sara C EmrichDepartment of Neurosurgery, Stanford University School of Medicine, 213 Quarry Road, Stanford, CA, 94304, USA.
Armine TayagDepartment of Neurosurgery, Stanford University School of Medicine, 213 Quarry Road, Stanford, CA, 94304, USA.
Susan M HinikerDepartment of Neurosurgery, Stanford University School of Medicine, 213 Quarry Road, Stanford, CA, 94304, USA.
David J ParkDepartment of Neurosurgery, Stanford University School of Medicine, 213 Quarry Road, Stanford, CA, 94304, USA. djpark@stanford.edu.
Steven D ChangDepartment of Neurosurgery, Stanford University School of Medicine, 213 Quarry Road, Stanford, CA, 94304, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveBrain metastases (BM) of peripheral neural crest tumors (PNCTs) are rare and bear a poor prognosis. Only a small number of prior studies document treatment of PNCT BM, with outcomes of stereotactic radiosurgery (SRS) limited to case reports. This study aimed to evaluate the efficacy and safety of SRS for PNCT BM, comparing it with alternative treatment approaches.

methodsWe retrospectively reviewed patients treated for PNCT at our institution between 2001 and 2024. Demographic, clinicopathologic, and treatment data were collected. Survival outcomes were estimated using Kaplan-Meier analysis. Local tumor control (LTC), progression-free survival (PFS), and overall survival (OS) rates were analyzed for the SRS-group and non-SRS cohort.

resultsWe identified 8 patients with PNCTs, with a total of 15 BM treated during the study period. Of these, 3 patients with 6 tumors underwent SRS, and 5 patients with 9 tumors received radiotherapy, craniotomy, or chemotherapy. The SRS cohort had a LTC rate of 100%, with an OS of 33.3% at 1-year follow up. Mean OS was 20.7 months (95% CI, 0–46.6). LTC in the group treated with other modalities was 71%, with an OS of 60% at 1-year follow up. Mean OS was 56.2 months (95% CI, 17.8–94.6).

conclusionSRS provided excellent local control of PNCT BM at 1-year follow-up without significant adverse radiation effects, supporting its potential as a viable minimally invasive option, especially for patients at higher risk from surgery or conventional radiotherapy. Larger prospective studies are needed to clarify the role of SRS in this rare population.

Indexed as

Brain NeoplasmsRadiosurgeryAdrenal Gland NeoplasmsAdultFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateBrain metastasesCNS cancerGanglioneuroblastomaNeural crest tumorsNeuroblastomaNeurosurgeryRadiosurgery

Identifiers

PMID41182459

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.